Granted Patent
B2
US 12,409,176 · App. 18/621,067 · Granted Sep 9, 2025
Methods of treating acute depression
Inventors:
Gretchen Snyder (New York, NY); Robert Davis (San Diego, CA); Lawrence P. Wennogle (Steamboat Springs, CO)
Assignee:
INTRA-CELLULAR THERAPIES, INC.
A61K31/4985A61K9/006A61K31/13A61K31/135A61K31/137A61K31/138A61K31/155A61K31/165A61K31/197A61K31/343A61K31/36A61K31/38A61K31/381A61K31/42A61K31/485A61K31/55A61K31/5513A61K38/07A61P25/24
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A/D2 receptor ligand, e.g. lumateperone.
Claims (14)
1. A method of treating acute depression, comprising administering to a patient in need thereof, a therapeutically effective amount of a Compound of Formula I:
wherein the Compound of Formula I is in the form of the tosylate salt,
wherein the method comprises once daily administration of a unit dosage for oral administration in the form of a tablet or capsule comprising the compound of Formula I in tosylate salt form in an amount equivalent to 1 to 60 mg of free base, and a pharmaceutically acceptable diluent or carrier; and
wherein the acute depression is a depressive episode associated with bipolar disorder.
2. The method according to claim 1 , wherein the depressive episode is selected from acute major depressive episode, acute short-duration depressive episode, and acute recurrent brief depressive episode.
3. The method according to claim 1 , wherein the method further comprises the concurrent administration of an NMDA receptor antagonist.
4. The method according to claim 1 , wherein the method further comprises the concurrent administration of a NMDA receptor allosteric modulator.
5. The method according to claim 1 , wherein the method provides the patient with an acute response to treatment with the Compound of Formula I.
6. The method according to claim 1 , wherein the patient has not responded to, or has not responded adequately to, or who suffers undesirable side effects from, treatment with another antidepressant agent.
7. The method according to claim 1 , wherein the Compound of Formula I is administered as monotherapy.
8. The method according to claim 1 , wherein the method does not put the patient at risk for sedation, dissociation, abuse, misuse, or suicidal ideation, or does not result in hypertension within four hours after administration of a dose of the compound of Formula I.
9. The method according to claim 1 , wherein the depressive episode is an acute major depressive episode.
10. The method according to claim 1 , wherein the depression is alleviated within one week of treatment.
11. The method according to claim 1 , wherein the patient shows an acute response to treatment within less than 2 weeks of treatment.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 15, 2024
From: SNYDER, GRETCHEN; DAVIS, ROBERT; WENNOGLE, LAWRENCE P.
To: INTRA-CELLULAR THERAPIES, INC.
Reel/Frame 067421/0534 →
Continuity (5)
Continuation
16981639
Provisional Application
62780004
· Dec 14, 2018
Provisional Application
62682582
· Jun 8, 2018
Provisional Application
62644355
· Mar 16, 2018
References Cited (225)
US 4136145A
· Fuchs et al.
· 1979
[cited by applicant]
US 4238607A
· Rajagopalan
· 1980
[cited by applicant]
US 4389330A
· Tice et al.
· 1983
[cited by applicant]
US 4530840A
· Tice et al.
· 1985
[cited by applicant]
US 5004602A
· Hutchinson
· 1991
[cited by applicant]
US 5114976A
· Norden
· 1992
[cited by applicant]
US 5151419A
· Perenyi et al.
· 1992
[cited by applicant]
US 5538739A
· Bodmer et al.
· 1996
[cited by applicant]
US 5629003A
· Horstmann et al.
· 1997
[cited by applicant]
US 5763476A
· Delbressine et al.
· 1998
[cited by applicant]
US 5922338A
· Brich et al.
· 1999
[cited by applicant]
US 5948430A
· Zerbe et al.
· 1999
[cited by applicant]
US 6544599B1
· Mesens et al.
· 2003
[cited by applicant]
US 6548493B1
· Robichaud et al.
· 2003
[cited by applicant]
US 6552017B1
· Robichaud et al.
· 2003
[cited by applicant]
US 6552024B1
· Chen et al.
· 2003
[cited by applicant]
US 6699852B2
· Robichaud et al.
· 2004
[cited by applicant]
US 6713471B1
· Robichaud et al.
· 2004
[cited by applicant]
US 6849619B2
· Robichaud et al.
· 2005
[cited by applicant]
US 6929803B2
· Wong et al.
· 2005
[cited by applicant]
US 7071186B2
· Robichaud et al.
· 2006
[cited by applicant]
US 7081455B2
· Robichaud et al.
· 2006
[cited by applicant]
US 7183282B2
· Robichaud et al.
· 2007
[cited by applicant]
US RE39679E
· Robichaud et al.
· 2007
[cited by applicant]
US RE39680E
· Robichaud et al.
· 2007
[cited by applicant]
US 7238690B2
· Robichaud et al.
· 2007
[cited by applicant]
US 7601740B2
· Weiner et al.
· 2009
[cited by applicant]
US 7645752B2
· McDevitt et al.
· 2010
[cited by applicant]
US 7998971B2
· Barlow et al.
· 2011
[cited by applicant]
US 8309722B2
· Tomesch et al.
· 2012
[cited by applicant]
US 8414922B2
· Bryson et al.
· 2013
[cited by applicant]
US 8598119B2
· Mates et al.
· 2013
[cited by applicant]
US 8648077B2
· Tomesch et al.
· 2014
[cited by applicant]
US 8652378B1
· Yang et al.
· 2014
[cited by applicant]
US 8779139B2
· Seeman et al.
· 2014
[cited by applicant]
US 8791138B2
· Seeman et al.
· 2014
[cited by applicant]
US 8835459B2
· Kottayil et al.
· 2014
[cited by applicant]
US 8900497B2
· Yang et al.
· 2014
[cited by applicant]
US 8900498B2
· Yang et al.
· 2014
[cited by applicant]
US 8906277B2
· Yang et al.
· 2014
[cited by applicant]
US 8993572B2
· Mates et al.
· 2015
[cited by applicant]
US 9108340B2
· Yang et al.
· 2015
[cited by applicant]
US 9168258B2
· Mates et al.
· 2015
[cited by applicant]
US 9199995B2
· Tomesch et al.
· 2015
[cited by applicant]
US 9216175B2
· Amancha et al.
· 2015
[cited by applicant]
US 9315504B2
· Tomesch et al.
· 2016
[cited by applicant]
US 9371324B2
· Mates et al.
· 2016
[cited by applicant]
US 9393192B2
· Yam et al.
· 2016
[cited by applicant]
US 9427412B2
· Bryson et al.
· 2016
[cited by applicant]
US 9428506B2
· Mates et al.
· 2016
[cited by applicant]
US 9586960B2
· Tomesch et al.
· 2017
[cited by applicant]
US 9616061B2
· Mates et al.
· 2017
[cited by applicant]
US 9708322B2
· Li et al.
· 2017
[cited by applicant]
US 9745300B2
· Mates et al.
· 2017
[cited by applicant]
US 9751883B2
· Tomesch et al.
· 2017
[cited by applicant]
US 9956227B2
· Vanover et al.
· 2018
[cited by applicant]
US RE48825E
· Tomesch et al.
· 2021
[cited by applicant]
US RE48839E
· Mates et al.
· 2021
[cited by applicant]
US 20110269777A1
· Bachurin et al.
· 2011
[cited by applicant]
US 20150080404A1
· Mates et al.
· 2015
[cited by applicant]
US 20200157100A1
· Li
· 2020
[cited by applicant]
US 20200392135A1
· Wennogle et al.
· 2020
[cited by applicant]
US 20210000822A1
· Mates et al.
· 2021
[cited by applicant]
US 20210008065A1
· Li et al.
· 2021
[cited by applicant]
US 20210186962A1
· Davis et al.
· 2021
[cited by applicant]
US 20230312573A1
· Li et al.
· 2023
[cited by applicant]
US 20230372336A1
· Dutheil et al.
· 2023
[cited by applicant]
GB 1476087
· 1977
[cited by applicant]
WO 2015085004
· 2015
[cited by applicant]
WO 2017120012A1
· 2017
[cited by applicant]
WO WO2018031535
· 2018
[cited by applicant]
Intra-Cellular Therapies, Inc., “Corporate Presentation,” (Sep. 24, 2019), downloaded from https://ir.intracellulartherapies.com/static-files/93b08960-f01c-4864-aa22-8cadb3539753 (last accessed Mar. 13, 2023).
[cited by applicant]
Aiken, C., “An Overview of Atypical Antipsychotics for Bipolar Depression,” published on Jan. 3, 2020 at https://www.psychiatrictimes.com/view/overview-atypical-antipsychotics-bipolar-depression, 11 pages.
[cited by applicant]
Angst et al. “Prevalence and Characteristics of Undiagnosed Bipolar Disorders in Patients With a Major Depressive Episode”, Arch Gen Psychiatry, vol. 68(8), p. 701-709, (2011).
[cited by applicant]
Bobo et al., “Fluoxetine and Olanzapine Combination Therapy in Treatment-resistant Major Depression: Review of Efficacy and Safety Data,” Expert Opinion on Pharmacotherapy, vol. 10, No. 13, p. 2145-2159, (2009).
[cited by applicant]
Bryan-Lluka et al., “Potencies of Haloperidol Metabolites as Inhibitors of the Human Noradrenaline, Dopamine and Serotonin Transporters in Transfected COS-7 Cells,” Naunyn-Shemiedeberg's Arch Pharmacol, vol. 360, pp. 10…
[cited by applicant]
Calabrese et al., “Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial,” American Journal of Psychiatry, vol.…
[cited by applicant]
“Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar,” ClinicalTrials.gov (Identifier: NCT02600494), 5 pages, (2015).
[cited by applicant]
Coyle et al., Dialogues Clin Neurosci., vol. 12, No. 3, p. 359-382, (2010).
[cited by applicant]
Darmani, et al., “Do Functional Relationships Exist Between 5-HT
[cited by applicant]
Davis, et al., “ITI-007 in the Treatment of Schizophrenia: From Novel Pharmacology to Clinical Outcomes,”
[cited by applicant]
Davis et al., “ITI-007: A Novel Treatment for Behavioral Disturbances Associated with Dementia and Related Disorders,” Clinical Trials in Alzheimer's Disease (CTAD) Congress 2014 (2014) (poster presentation).
[cited by applicant]
Davis et al., “Rationale for the Development of Low Doses of ITI-007 for the Treatment of Behavioral Disturbances Associated with Dementia,” The Journal of Prevention of Alzheimer's Disease, 2(4):302 (2015) (Clinical Tr…
[cited by applicant]
Davis, et al., “ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers,” Psychopharmacology, vol. 232, pp. …
[cited by applicant]
Davis, et al., “Lumateperone (ITI-007), A Novel Drug in Development for the Treatment of Agitation in Patients with Dementia, including Alzheimer's Disease: Rationale and Clinical Design,” The Journal of Prevention of A…
[cited by applicant]
Del-Monte et al., Psychiatry Res., vol. 210, p. 29-35, (2013).
[cited by applicant]
Docherty et al., Schizophrenia Res., vol. 120, p. 199-203, (2010).
[cited by applicant]
Gramigna, J, “Lumateperone Safe, Effective for Depressive Symptoms Among Patients with Bipolar Disorders,” American Society of Clinical Psychopharmacology Annual Meeting, Jun. 2, 2020, 3 pages.
[cited by applicant]
Harvey, et al., “Lumateperone Improves Negative Symptoms Related to Emotional Experience (Avolition) in Patient with Schizophrenia,” Abstract presented at the American Society of Clinical Psychopharmacology (ASCP) Annua…
[cited by applicant]
Helfer et al., Am J Psychiatry, vol. 173, No. 9, p. 876-886, (2016).
[cited by applicant]
Hlavinka, E., “Schizophrenia Tx Eases Depression in Bipolar Disorder: Lumateperone Offers Greater Rate of Response, Remission versus Placebo,” Medpage Today, 7 pages, (2020); https://www.medpagetoday.com/meetingcoverage…
[cited by applicant]
Howes et al., J Psychopharmacol., vol. 29, No. 2, p. 97-115, (2015).
[cited by applicant]
Kantrowitz, J.T., “The Potential Role of Lumateperone—Something Borrowed? Something New?,” JAMA Psychiatry, vol. 77, No. 4, p. 343-344, (2020); Abstract Only.
[cited by applicant]
Khorana, et al., “Gamma-Carbolines: Binding at 5-HT5A Serotonin Receptors,”
[cited by applicant]
Kumar et al., “Lumateperone: A New Treatment Approach for Neuropsychiatric Disorders,” Drugs of Today, vol. 54, No. 12, p. 713-719, (2018).
[cited by applicant]
Lammers, et al., “Risperidone Long-acting Injection in Schizophrenia Spectrum Illnesses Compared to First Generation Depot Antipsychotics in an Outpatient Setting in Canada,” BMC Psychiatry, vol. 13, No. 155, 9 pages, (…
[cited by applicant]
Lee, et al. “Novel, Highly Potent, Selective 5-HT
[cited by applicant]
Li, et al., “Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders,”
[cited by applicant]
Lieberman, J.A., et al., “ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial,” Biol. Psychiatry, vol. 79, No. 12, pp. 952-961, (2015).
[cited by applicant]
Liebermann et al., “ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial,” Biological Psychiatry, vol. 79, p. 952-961, (2016).
[cited by applicant]
Lindstrom et al., Nord J Psychiatry, vol. 47, No. 4, p. 257-263, (1993).
[cited by applicant]
Makadia et al., “Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier,” Polymers (Basel), vol. 3, No. 3, pp. 1377-1397, (2011).
[cited by applicant]
Marek et al. Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders. Neuropsychopharmacology, 2003. vol. 28, pp. 402-412. (Year: 2003).
[cited by applicant]
Mass et al., Schizophrenia Bull., vol. 26, No. 1, p. 167-177, (2000).
[cited by applicant]
McIntyre et al., “Rapid-acting Antidepressants in Psychiatry: Psychedelics, Episodic Treatments, Innovation, and Clarion Call for Methodologic Rigor in Drug Development,” Expert Opinion on Drug Safety, vol. 21, No. 6, p…
[cited by applicant]
Medisorb Fact Sheet in Medisorb Microspheres Technology (Jan. 2009) at https://static.secure.website/wscfus/6472891/uploads/Medisorb.pdf (retrieved from the internet May 18, 2020) (Year: 2009).
[cited by applicant]
Menard, et al., “Social stress induces neurovascular pathology promoting depression,” Nature Neuroscience 20:1752-60 (2017).
[cited by applicant]
Möller and P Czobor, Eur Arch Psychiatry Clin Neurosci., vol. 265, p. 567-578, (2015).
[cited by applicant]
Mueller et al., “Detection of Depression in Acute Schizophrenia: Sensitivity and Specificity of 2 Standard Observer Rating Scales,” Can J Psychiatry, vol. 51, No. 6, pp. 387-392, (2006).
[cited by applicant]
O'Gorman et al., “Lumateperone (ITI-007): A Novel Investigational Agent with Broad Therapeutic Potential Across Multiple Neuropsychiatric Disorders,” Poster p. 1.g.038, European College of Neuropsychopharmacology (ECNP)…
[cited by applicant]
Palanisamy, M. et al., “Cellulose-Based Matrix Microspheres of Prednisolone Inclusion Complex; Preparation and Characterization.” American Association of Pharmaceutical Scientists PharmSciTech, vol. 12, No. 1, pp. 388-4…
[cited by applicant]
Perlis et al., “Clinical Features of Bipolar Depression Versus Major Depressive Disorder in Large Multicenter Trials”, Am J Psychiatry, vol. 163, p. 225-231, (2006).
[cited by applicant]
Press Release, “Intra-Cellular Therapies Announces Additional Results from Phase I/II Clinical Trail for ITI-007 in Healthy Geriatric Subjects and Patients With Dementia,” Intra-Cellular Therapies, Press Release Date: N…
[cited by applicant]
Press Release, “Intra-Cellular Therapies Presents Data on Symptom Improvement by Lumateperone on Negative Symptoms, Depression, and Social Function in Patients with Schizophrenia at the American Society of Clinical Psyc…
[cited by applicant]
Press Release, “Intra-Cellular Therapies Announces Positive Top-Line Results from a Phase 3 Trial of Lumateperone in Patient with Bipolar Depression,” Intra-Cellular Therapies, Press Release Date: Jul. 8, 2019.
[cited by applicant]
Puig et al., “Serotonin and Prefrontal Cortex Function: Neurons, Networks, and Circuits,” Mol. Neurobiol., 44(3):449-464 (2011).
[cited by applicant]
Rainer, M.K., “Risperidone Long-acting Injection: A Review of its Long Term Safety and Efficacy,”
[cited by applicant]
Rummel et al., Schizophrenia Res., vol. 80, p. 85-97, (2007).
[cited by applicant]
Satlin, et al., “ITI-007 (Lumateperone) for the Treatment of Agitation in Patients with Dementia, including Alzheimer's Disease,” Poster P2-032, Alzheimer's Assoc. International Conference 2018 (2018).
[cited by applicant]
Satlin, et al., “ITI-007 (Lumateperone) for the Treatment of Agitation in Patients with Dementia, including Alzheimer's Disease,” Alzheimer's & Dementia 14(7) (Suppl.): P678-79 (2018) (Alzheimer's Assoc. International C…
[cited by applicant]
Sepehry et al., J Clin Psychiatry, vol. 68, No. 4, p. 604-610, (2007).
[cited by applicant]
Silver et al., Neurotherapeutics, vol. 6, p. 86-93, (2009).
[cited by applicant]
Singh et al., The British Journal of Psychiatry, vol. 197, p. 174-179, (2010).
[cited by applicant]
Snyder, et al., “Functional Profile of a Novel Modulator of Serotonin, Dopamine, and Glutamate Neurotransmission,”
[cited by applicant]
Tohen, M., et al., “Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression,” Arch Gen Psychiatry, vol. 60, pp. 1079-1088, (2003).
[cited by applicant]
Vanover et al., Abstracts of the 13th International Congress on Schizophrenia (ICOSR) (Apr. 2-6, 2011), Schizophrenia Bull., 37 Suppl. 1, p. 325, (Mar. 2011).
[cited by applicant]
Vanover, et al., “Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia,”
[cited by applicant]
Vanover, et al., “A Novel Approach to Address an Unmet Need in the Treatment of Schizophrenia and Depression: Lumateperone, an Innovative Modulator of Dopamine, Serotonin, and Glutamate,” Abstract presented at the Ameri…
[cited by applicant]
Vanover, K., et al., “ITI-007: A Novel Therapy for the Treatment of Schizophrenia and Related Psychoses,” International Clinical Psychopharamcology, vol. 26, e56, 1 page, (2011).
[cited by applicant]
Vyas, P., et al., “An Evaluation of Lumateperone Tosylate for the Treatment of Schizophrenia,” Expert Opinion on Pharmacotherapy, vol. 21, No. 2, pp. 139-145, (2020); https://doi.org/10.1080/14656566.2019.1695778.
[cited by applicant]
Wang et al., “Rapid-acting Antidepressants Targeting Modulation of the Glutamatergic System: Clinical and Preclinical Evidence and Mechanisms,” General Psychiatry, vol. 35, No. e100922, 6 pages (2022).
[cited by applicant]
Wennogle, et al., “Activation of NMDA and AMPA Receptors by Lumateperone (ITI-007): Implications for Antidepressant Activity,” Abstract presented at the 2017 Collegium Internationale Neuro-Psychopharmacologicum (CINP) T…
[cited by applicant]
Zhang et al., “The In Vivo Effects of Olanzapine and Other Antipsychotic Agents on Receptor Occupancy and Antagonism of Dopamine D
[cited by applicant]
“ACNP 58th Annual Meeting: Poster Session II: Abstracts Collection” Neuropsychopharmacology, vol. 44, p. 230-384, (2019); 3 parts.
[cited by applicant]
“Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression,” ClinicalTrials.gov, 6 pages, Nov. 9, 2015.
[cited by applicant]
Barman, R. et al., “Newer Antipsychotics: Brexpiprazole, Cariprazine, and Lumateperone: A Pledge or Another Unkept Promise?,” World J. Psychiatr., vol. 11, No. 12, pp. 1228-1238, (2021).
[cited by applicant]
Correll, C. et al., “Efficacy and Safety of Lumateperone for Treatment of Schizophrenia A Randomized Clinical Trial,” JAMA Psychiatry, vol. 77, No. 4, pp. 349-358, (2020).
[cited by applicant]
Dutheil, S., et al. “Lumateperone Normalizes Pathological Levels of Acute Inflammation through Important Pathways Known to Be Involved in Mood Regulation,” The Journal of Neuroscience, vol. 43, No. 5, pp. 863-877, (2023…
[cited by applicant]
Galea, I., “The Blood-Brain Barrier in Systemic Infection and Inflammation,” Cellular & Molecular Immunology, vol. 18, p. 2489-2501, (2021).
[cited by applicant]
Mazza, M. et al, “Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders,” CNS & Neurological Disorders—Drug Targets, vol. 19, pp. 243-247, (2020).
[cited by applicant]
Snyder, G. et al., “Chapter 11: A review of the pharmacology and clinical profile of lumateperone for the treatment of schiophrenia,” Advances in Pharmacology, vol. 90, pp. 253-276, 31 pages, (2021).
[cited by applicant]
Suppes, T. et al., “Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial,” Bipolar Disorders, vol. 25, pp. 478-488, 11 pages, (2023).
[cited by applicant]
Vanover, K. et al., “50. ITI-007, an Investigational New Antipsychotic Drug with a Novel Pharmacological Profile, is Safe and Well-Tolerated with Early Clinical Signs for Efficacy in Patients with Stabilized Schizophren…
[cited by applicant]
Vanover, K. et al., “Safety, Pharmacokinetics and Early Signals for Efficacy with ITI-007, A Novel Investigational New Drug for the Treatment of Schizophrenia and Related Disorders,” Schizophrenia Bulletin, vol. 37, Sup…
[cited by applicant]
Warner-Schmidt, J. et al., “Antidepressant Effects of Selective Serotonin Reuptake Inhibitors (SSRIs) are Attenuated by Antiinflammatory Drugs in Mice and Humans,” PNAS, vol. 108, No. 22, pp. 9262-9267, (2011).
[cited by applicant]
Witkin, J. et al., “Chapter 3: Rapid-acting Antidepressants,” Advances in Pharmacology, vol. 86, 50 pages, (2019).
[cited by applicant]
“Highlights of Prescribing Information CAPLYTA (lumateperone) capsules, for oral use,” Label—Prescribing Information, 16 pages, (2019); https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf.
[cited by applicant]
“Clinical Practice Guideline—Management of Bipolar Disorder in Adults”, Department of Veterans Affairs and the Department of Defense, 176 pages, (2010).
[cited by applicant]
“Rating Scales and Safety Measurements in Bipolar Disorder and Schizophrenia—A Reference Guide,” Psychopharmacol. Bull., vol. 47, No. 3, p. 77-109 (2017).
[cited by applicant]
Altschuler et al., “Lower Switch Rate in Depressed Patients with Bipolar II than Bipolar I Disorder Treated Adjunctively with Second-Generation Antidepressants,” Am. J. Psychiatry, vol. 163, No. 2, p. 313-315 (2006).
[cited by applicant]
Bastin, R. et al., “Salt Selection and Optimized Procedures for Pharmaceutical New Chemical Entities,” Organic Process and Research Development, vol. 4, No. 5, pp. 427-435, (2000).
[cited by applicant]
Cascade et al., “Antidepressants in Bipolar Disorder,” Psychiatry (Edgmont), vol. 4, No. 3, p. 56-58 (2007).
[cited by applicant]
Celada et al., “The Therapeutic Role of 5-HT1A and 5-HT2A Receptors in Depression,” Rev. Psychiatr. Neurosci., vol. 29, No. 4, pp. 252-265 (2004).
[cited by applicant]
Citrome et al., “Toward Convergence in the Medication Treatment of Bipolar Disorder and Schizophrenia,” Harv. Rev. Psychiatry, vol. 13, No. 1, p. 28-42 (2005).
[cited by applicant]
Defendants' Joint Initial Invalidity Contentions, Ex. M ('617 Patent),
[cited by applicant]
Ghaemi, N., “Expert Commentary-Antidepressants in Bipolar Disorder,” Psychiatry (Edgmont), vol. 4, No. 3, pp. 56-58 (2007).
[cited by applicant]
Gould, P., “Salt selection for basic drugs,” Int'l J. Of Pharms., vol. 33, p. 201-217 (1986).
[cited by applicant]
Intra-Cellular Press Release, “Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual Meeting of the American College of Neuropsychopharmacology” (Dec. 7, 2017).
[cited by applicant]
Intra-Cellular Press Release, “Intra-Cellular Therapies Reports Initiation of Patient Enrollment for ITI-007 Phase I Clinical Trials in Bipolar Depression”, (Dec. 23, 2015).
[cited by applicant]
Montgomery et al., “Pharmacotherapy of Depression and Mixed States in Bipolar Disorder,” J. Affect. Disord., vol. 59, pg. S39-S56 (2000).
[cited by applicant]
Mortimer, “Symptom Rating Scales and Outcome in schizophrenia,” Brit. J. Psychiatry, vol. 191, Suppl. No. 50, pg. s7-s14 (2007).
[cited by applicant]
Press Release, “Intra-Cellular Therapies, Inc. Receives Exclusive License for Central Nervous System Compounds from Bristol-Myers Squibb Company,” Intra-Cellular Therapies, Inc. Press Release Date: Jun. 1, 2005.
[cited by applicant]
Shah, et al., “Clinical Practice Guidelines for Management of Bipolar Disorder,” Indian J. Psychiatry, 59:51-66 (2017).
[cited by applicant]
Yatham, L., “A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder,” Journal of Affective Disorders, vol. 128, Suppl. 1, pp. S21-S28, (2011).
[cited by applicant]
Yatham, L.N., “Atypical Antipsychotics for Bipolar Disorder,” Psychiatr. Clin. N. Am., vol. 28, No. 2, p. 325-347 (2005).
[cited by applicant]